Glucagon-like peptide (GLP)-1 receptor agonists (GLP-1RAs), which are glucose-lowering agents based on the gut-derived incretin-hormone GLP-1, are now widely used in the management of type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.